Skip to main content

Table 1 preliminary magnitude of clinical benefit grade based on PFS

From: Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial

Grade 3 HR ≤0.65 and gain ≥3 months
Grade 2 HR ≤0.65 but gain < 3 months
Grade 1 HR > 0.65
  1. PFS progression-free survival, HR hazard ratio (thresholds refer to the lower extreme of the 95% confidence interval)